KEI on Moderna’s Oct 8, 2020 Statement on Intellectual Property Matters during the COVID-19 Pandemic

(More on KEI’s work on coronavirus here: https://www.keionline.org/coronavirus, and on Moderna, here: https://www.keionline.org/moderna) Oct 8, 2020 Moderna’s statement on intellectual property matters during the COVID-19 pandemic is very good, and should be matched by every manufacturer of a therapeutic, vaccine… Continue Reading

DARPA letter to KEI confirming investigation of Moderna for failure to report government funding in patent applications

On Friday, September 18, 2020, KEI received a letter from the Defense Advanced Research Projects Agency (DARPA) confirming that the agency was investigating Moderna for failure to report government funding in patent applications. The Financial Times and other outlets had… Continue Reading

BARDA is investigating Moderna’s failures to disclose BARDA funding in patent applications

(More on Moderna here: https://www.keionline.org/moderna) KEI received a letter Dr. Gary Disbrow, the Acting Director of BARDA, just before noon today. BARDA2KEI.Moderna.Patent.Disclosures.20200903 The BARDA investigation follows the announcement on Saturday that DARPA was also investigating DARPA’s failures to disclose DARPA… Continue Reading

KEI asks DOD to investigate failure to disclose DARPA funding in Moderna patents

(More on Moderna here: https://www.keionline.org/moderna) Luis Gil Abinader has taken a deep dive into Moderna’s surprising practice of never declaring government funding in its 126 patents and 154 patent applications, despite having had funding from multiple federal agencies. One outcome… Continue Reading

Joint letter to Dr. Fauci at NIAID, regarding the geographic scope of RNAceuticals HIV patent license, asks that exclusivity not extend to countries with low and moderate incomes

Below is a letter from several individuals and groups, asking that NIAID not grant exclusive rights in a HIV patent license for South Africa, India and other low income countries. (PDF version here) The license is to RNAceuticals, a firm… Continue Reading